INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 43h ago
House PTR3h ago
SEC 13F3h ago
Robinhood Chain3h ago

Most active filers · 30d

  1. 01FWFogarty Patrick W0B / 206S206 trades$1.10M
  2. 02Kurtz George0B / 202S202 trades$48.06M
  3. 03SPSaba Capital Management, L.P.67B / 19S · 11 late86 trades$21.51M
  4. 04NYNissan Yitzhak82B / 0S · 79 late82 trades$2.61M
  5. 05ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  6. 06AJAllaire Jeremy0B / 50S50 trades$4.26M
  7. 07Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  8. 08SJSheena Jonathan0B / 45S45 trades$3.01M
  9. 09SISarowitz Steven I2B / 34S36 trades$21.18M
  10. 10SLSpeiser Michael L0B / 35S35 trades$14.00M

Cluster activity · 60d

  1. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  2. BUYMTDRMatador Resources CoNov 5 – Nov 189 insiders$1.02M
  3. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 168 insiders$42.58M
  4. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  5. SELLMGNIMAGNITE, INC.Nov 5 – Nov 178 insiders$2.77M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  8. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M

Form 4 transactions

73,431 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
29
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$36K
94 sh
Jan 12, 2026
Page 1503 of 1836
← PrevNext →
Jan 14, 2026
traded Jan 12, 2026
+2d
SEC Form 4

Evidence

29
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$33K
88 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

29
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$79K
890 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

29
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$215K
2,419 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

29
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$7,822
21 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

28
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$322K
3,648 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

28
Wood Anthony J.Director, CEO and Chairman BOD, 10% Owner
ROKUROKU, INC
Open-market sale · 10b5-1 plan
SELL$1.38M
12.8K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

28
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$322K
3,647 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

28
BG
Birkenbeuel GaryDirector
TTEKTETRA TECH INC
Grant or award
A—
5,270 sh
Jan 1, 2025Jan 14, 2026
traded Jan 1, 2025
+378dSEC Form 4

Evidence

27
Wood Anthony J.Director, CEO and Chairman BOD, 10% Owner
ROKUROKU, INC
Open-market sale · 10b5-1 plan
SELL$45K
400 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

27
SR
Soule Randy10% Owner
SAFXXCF Global, Inc.
Open-market sale
SELL$32K
200.0K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

27
Wood Anthony J.Director, CEO and Chairman BOD, 10% Owner
ROKUROKU, INC
Open-market sale · 10b5-1 plan
SELL$23K
200 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

27
SR
Soule Randy10% Owner
SAFXXCF Global, Inc.
Open-market sale
SELL$11K
73.0K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

27
MC
Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
OLMAOlema Pharmaceuticals, Inc.
Open-market sale
SELL$5,698
200 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

27
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$1.32M
15.0K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

27
FM
Frank MalcolmDirector
FDSFACTSET RESEARCH SYSTEMS INC
Option exercise
M$535K
2,572 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

27
DP
Duffy Sean P.Director, Chief Executive Officer
OMDAOmada Health, Inc.
Option exercise
M$588K
230.5K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

27
SR
Soule Randy10% Owner
SAFXXCF Global, Inc.
Open-market sale
SELL$32K
200.0K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

26
DK
DeHoff KateSee Remarks
JOBYJoby Aviation, Inc.
Open-market sale · 10b5-1 plan
SELL$416K
28.3K sh
Jan 14, 2026Jan 14, 2026
traded Jan 14, 2026
+0dSEC Form 4

Evidence

26
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$26K
296 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

26
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$26K
296 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

25
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$126K
1,446 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

25
RC
Ravid ChagayDirector, Chief Executive Officer
SDOTSadot Group Inc.
Open-market sale
SELL$4,442
1,305 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

25
BC
Billingsley ChesterDirector, Chief Executive Officer, 10% Owner
MNTRMentor Capital, Inc.
Open-market purchase
BUY$106
1,200 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

25
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$107K
1,216 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

25
ZF
Zalenko Neal F.Director
GRFEAGLE CAPITAL GROWTH FUND, INC.
Open-market purchase
BUY$2,574
234 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

25
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$126K
1,446 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

25
Wood Anthony J.Director, CEO and Chairman BOD, 10% Owner
ROKUROKU, INC
Open-market sale · 10b5-1 plan
SELL$838K
7,799 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

24
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$308K
3,573 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

24
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$268K
3,191 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

24
BG
Birkenbeuel GaryDirector
TTEKTETRA TECH INC
Option exercise
M—
2,050 sh
Jan 1, 2025Jan 14, 2026
traded Jan 1, 2025
+378dSEC Form 4

Evidence

24
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$518K
5,948 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

24
BG
Birkenbeuel GaryDirector
TTEKTETRA TECH INC
Option exercise
M—
2,050 sh
Jan 1, 2025Jan 14, 2026
traded Jan 1, 2025
+378dSEC Form 4

Evidence

23
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$73K
199 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

23
JC
Jay ColleenDirector
COOCOOPER COMPANIES, INC.
Option exercise
M$278K
7,064 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

23
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$56K
155 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

23
DK
DeHoff KateSee Remarks
JOBYJoby Aviation, Inc.
Open-market sale · 10b5-1 plan
SELL$105K
7,092 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

23
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$80K
220 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

22
GS
Gatzke Carla SSecretary and VP of Human Reso
DAKTDAKTRONICS INC /SD/
Gift
G—
1,800 sh
Dec 23, 2025Jan 14, 2026
traded Dec 23, 2025
+22dSEC Form 4

Evidence

22
KA
Kurtenbach Reece ADirector
DAKTDAKTRONICS INC /SD/
Gift
G—
1,800 sh
Dec 23, 2025Jan 14, 2026
traded Dec 23, 2025
+22dSEC Form 4

Evidence